Physician profile
Michael Salinas
NPI 1336530252
$4,448.99
in general payments reported to CMS, 2019-2025
19 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $971 · 2022: $789 · 2023: $1,082 · 2024: $496 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,525 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,525.13 |
| Education | $164.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $656.05 | 2021-2025 | Caplyta |
| Indivior INC. | $628.34 | 2021-2025 | Perseris, Sublocade |
| Vanda Pharmaceuticals INC. | $446.24 | 2021-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $414.62 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $376.04 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $333.25 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $333.18 | 2021-2025 | Invega Sustenna, Spravato |
| Lundbeck LLC | $299.21 | 2021-2025 | Rexulti |
| Alkermes, INC. | $270.04 | 2021-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $231.35 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $132.61 | 2022-2023 | Auvelity |
| Abbvie INC. | $116.67 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $76.44 | 2022-2023 | Qelbree |
| Noven Therapeutics, LLC | $31.30 | 2021-2024 | Secuado |
| Idorsia Pharmaceuticals US INC | $29.62 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $23.34 | 2024 | Azstarys |
| Allergan, INC. | $18.01 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.40 | 2022 | |
| Luye Pharma (USA) Ltd. | $16.28 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Salinas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.